In Vivo Testing of Radiosensitizers
Most anticancer drugs are designed to exploit the more rapid proliferation of tumour cells than of normal cells, and are cytotoxic in certain phases of the cell cycle. Nitro-imidazoles as tumour radiosensitizers are quite different since they have an equal sensitizing action on cycling and non-cycling cells, and on cells at any stage in their cell cycle. Their tumour-specific action relates to the presence of a large fraction of hypoxic cells in tumours, and not in normal tissues.
KeywordsNerve Conduction Velocity Hypoxic Cell Enhancement Ratio Sensory Peripheral Neuropathy Increase Drug Dose
Unable to display preview. Download preview PDF.
- 3.G. E. Adams, E. D. Clarke, I. R. Flockhart, R. S. Jacobs, D. S. Sehmi, I. J. Stratford, P. Wardman, M. E. Watts, J. Parrick, R. G. Wallace and C. E. Smithen, Structure- activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency, Int. J. Radiat. Biol., 35: 133 (1979).Google Scholar
- 12.J. Denekamp, D. G. Hirst, F. A. Stewart and N. H. A. Terry, Is tumour radiosensitization by misonidazole a general phenomenon? Brit. J. Cancer, 41:1 (1980).Google Scholar
- 17.J. Denekamp, N. J. McNally, J. F. Fowler and M. C. Joiner, Misonidazole in fractionated radiotherapy: little and often? Brit. J. Radiol., (in press) (1980b).Google Scholar
- 19.D. G. Hirst, B. Vojnovic, I. J. Stratford and E. L. Travis, The effect of the radiosensitizer misonidazole on motor nerve conduction velocity in the mouse, Brit. J. Cancer, 37: Suppl. Ill: 237 (1978).Google Scholar
- 21.C. Clarke, K. B. Dawson, P. W. Sheldon, D. J. Chaplin, I. J. Stratford and G. E. Adams, A quantitative cytochemical method for assessing the neurotoxicity of misonidazole, in: “Radiation Sensitizers: Their use in the Clinical Management of Cancer”, L. W. Brady, ed., Masson Publishing Inc., New York. (1980).Google Scholar